Why the study?
Coronary microvascular obstruction during PCI for myocardial infarction negatively impacts prognosis, but its mechanisms are complex and effective treatments that fundamentally improve outcomes remain lacking.
Coronary microvascular obstruction during PCI for MI remains a significant prognostic challenge without a definitive therapeutic solution.
Answers are grounded in this paper and cite their sources.
No-reflow impairs post-PCI MI prognosis; leaves open targeted therapies beyond current indirect approaches.
Coronary microvascular obstruction (the no-reflow phenomenon) after percutaneous coronary interventions in diagnosed with myocardial infarction has a significant negative impact on both the short-term and long-term prognosis. The mechanisms underlying this disorder are heterogeneous and complex, and as such it is difficult to devise effective treatments and/or to predict specific outcomes. Modern therapeutic approaches have indirect cardioprotective effects and certainly reduce the risk of no-reflow. However, attempts to create a drug or method that fundamentally improve the prognosis in patients with coronary microvascular obstruction have been unsuccessful. Thus, the problem of myocardial reperfusion damage has not been solved and further study will be necessary to provide support for the search for new therapeutic modalities. The purpose of this review is to provide an analysis of relevant literature that focuses on the aetiology, pathogenesis, diagnosis, prognosis and treatment of the coronary microvascular obstruction during and after percutaneous coronary interventions in patients diagnosed with myocardial infarction. We searched using the Medline (PubMed), RSCI (eLIBRARY), Embase and Google Scholar databases for all relevant literature pertaining to this subject.
No takes yet. Share an insight, caveat, or question.
Фролов et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: